This 88-hour on-demand conference includes 64 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

This 6-hour, on-demand course will equip healthcare providers with the necessary tools to make a meaningful difference in the lives of women facing addiction.

This 1 hour and 45-minute on-demand session from the ASAM 57th Annual Conference addresses benzodiazepine management in outpatient settings, applying ASAM guidelines to cases and exploring tapering strategies and success definitions.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses co-occurring alcohol use disorder and psychiatric conditions, covering diagnostic tools, integrated treatment plans, and barrier-reduction strategies.

This 60-minute on-demand session from the ASAM 57th Annual Conference addresses loneliness in people with substance use disorders, exploring screening tools, brief interventions, and community-based advocacy strategies.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses promoting integrated SUD and mental health treatment, exploring level of care determination standards and clinical decision-support tools.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses addiction medication use in adolescents with SUD, including risk-benefit considerations, family involvement, and expanding treatment access.

This 60-minute on-demand session from the ASAM 57th Annual Conference addresses collaborative care for OUD with co-occurring mental disorders, featuring new research findings and implementation guidance.

This 6-hour course is an interactive, case-based course designed for healthcare providers who work with patients taking benzodiazepines.

In this episode of ASAM Practice Pearls, Drs. Stephen Taylor and Smita Das discuss co-occurring psychiatric and substance use disorders (SUD). They explore the most common psychiatric conditions seen alongside addiction, share strategies for distinguishing primary psychiatric disorders from substance-induced symptoms, and review approaches to screening, treatment planning, and integrated care. The conversation highlights practical screening tools, medication considerations, and populations with unique clinical needs, emphasizing the importance of treating both conditions concurrently.